Efficacy and Safety of Pazopanib in Treating Thyroid Cancer
Author Information
Author(s): Mederle Alexandra Laura, Stana Loredana Gabriela, Ilie Adrian Cosmin, Borza Claudia, Streian Caius Glad, Nistor Daciana, Cerbulescu Teodor, Belovan Biliana, Lascu Ana
Primary Institution: Victor Babes University of Medicine and Pharmacy
Hypothesis
This systematic review aims to evaluate the efficacy and safety of pazopanib in the treatment of thyroid cancer.
Conclusion
Pazopanib shows variable efficacy across thyroid cancer types, offering significant benefits in medullary thyroid carcinoma and refractory differentiated thyroid carcinoma, but limited impact in anaplastic thyroid carcinoma.
Supporting Evidence
- Pazopanib demonstrated clinical activity in RAI-refractory differentiated thyroid carcinoma with partial response rates ranging from 35.6% to 49%.
- In metastatic medullary thyroid carcinoma, pazopanib showed a modest partial response rate of 14.3%.
- Pazopanib showed minimal efficacy in anaplastic thyroid carcinoma, with no confirmed RECIST responses.
- Common adverse events included hypertension, diarrhea, and fatigue, with significant variability in treatment tolerability.
- Intermittent dosing of pazopanib did not improve outcomes compared to continuous dosing.
Takeaway
Pazopanib is a medicine that helps some people with thyroid cancer, but it doesn't work well for everyone, especially those with a very aggressive type of cancer.
Methodology
This systematic review included randomized controlled trials and phase II clinical trials that investigated the use of pazopanib in thyroid cancer, following PRISMA guidelines for data extraction and quality assessment.
Potential Biases
Potential publication bias cannot be excluded, as studies with negative results may be less likely to be published.
Limitations
The included studies varied in design, patient populations, and endpoints, which may have introduced heterogeneity; some studies had small sample sizes, limiting generalizability.
Participant Demographics
The studies included a total of 289 patients with varying demographics, including median ages ranging from 57.5 to 67 years and a mix of male and female participants.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website